Scott Thompson Show

Purdue Pharmaceuticals has reached a plea deal, agreeing to plead guilty to criminal charges over how it handled Oxtcontin. The deal allows them to sidestep paying billions in penalties. Guest: Dean L Fanelli, Ph.D, partner in the Intellectual Property Department of Seyfarth Shaw LLP’s Washington Office, with 20 years of experience in pharmaceutical and biotechnology management